你知道培美替尼的功效及副作用吗？

Pemetinib, developed by the American company Incyte, is the first small molecule drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of cholangiocarcinoma. Pemetinib has been granted orphan drug, breakthrough therapy and priority review designations by the FDA. Based on its good efficacy data in phase II clinical trials, pemetinib was approved by the FDA for accelerated approval on April 20, 2020. It is used for adult patients with previously treated unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 gene fusion or other rearrangements. The approved dosage form is oral tablets with specifications of 4.5, 9 and 13.5 mg. In March 2021, it was conditionally approved for marketing in Europe and launched in Japan in the same month. It is used for the treatment of cholangiocarcinoma in both Europe and Japan.

Pemetinib can inhibit the binding of FGFR1/2/3 to ligands, that is, inhibit the FGFR signaling pathway, thereby inhibiting the proliferation of tumor cells overexpressing FGFR1/2/3. Pemetinib inhibits the abnormal activation of the FGFR2 signaling pathway by inhibiting the binding of FGFR2 receptors to FGFR ligands, thereby inhibiting the occurrence, development and progression of cholangiocarcinoma.

: Swelling and pain in limbs or joints, diarrhea, nausea, weight loss, constipation, decreased urine output, blurred vision, floaters in the eyeballs, rapid heartbeat, loss of appetite, hair loss, headache, vomiting, muscle cramps, stomach pain, fatigue, joint pain, painful urination, seeing flashes of light or other vision changes, onychomycosis, taste changes, aphtha, dry mouth and/or dry skin, numbness or dry mouth, etc.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.